Abstract
The objective of the study is to evaluate the outcome of patients with seronegative spondyloarthritis continuing on sulphasalazine (SSZ) and methotrexate (MTX) after a short course of infliximab. Patients with seronegative spondyloarthritis on MTX and SSZ were given short course of infliximab therapy at 0, 2, 6 and 14 weeks. Outcome of these patients while continuing on MTX and SSZ was assessed. Clinical features, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were noted at baseline (pre-infliximab), 1 month, 3 months and last follow-up after last dose of infliximab infusion. Twenty-four patients were included in this study. The mean duration of follow-up was 9.1 months. Statistically significant reduction in tender and swollen joint count was noted at all the three visits as compared to baseline. Fall in ESR and CRP was statistically significant at 1 and 3 months, but not at last follow-up. Mean reduction in BASDAI at 1 month ,3 month and last follow-up after last infliximab dose were 3.907 (95% CI 2.98–4.83; p < 0.001), 4.53 (95% CI 3.56–5.49; p < 0.001) and 2.48 (95% CI 1.12–3.84; p = 0.002), respectively. Mean reduction in BASFI at 1 month, 3 months and last follow-up after last infliximab dose were 4.13 (95% CI 3.23–5.04; p < 0.001), 4.34 (95% CI 2.8–5.88; p < 0.001) and 2.38 (95% CI 0.86–3.90; p = 0.005), respectively. Continuing SSZ and MTX after short course of infliximab results in sustained improvement in our patients with seronegative spondyloarthritis in India.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R et al (2005) Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44(5):670–676
Baraliakos X, Braun J (2010) Anti-TNF-alpha therapy with infliximab in spondyloarthritides. Expert Rev Clin Immunol 6(1):9–19
Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439–444
de Vries HS, van Oijen MGH, de Jong DJ (2008) Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf 31(12):1135–1144
Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P et al (2010) Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 69(2):400–408
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104
Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42(11):2325–2329
Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM (2000) Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 29(3):160–162
Collantes-Estevez E, Muñoz-Villanueva MC, Zarco P, Torre-Alonso JC, Gratacós J, González C, Spanish Spondyloarthropathies Study Group et al (2005) Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. Rheumatology (Oxford) 44(12):1555–8
Cardiel MH, Londoño JD, Gutiérrez E, Pacheco-Tena C, Vázquez-Mellado J, Burgos-Vargas R (2003) Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies. Clin Exp Rheumatol 21(4):451–8
Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O’connor P et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64(11):1568–1575
Pérez-Guijo VC, Cravo AR, Castro MDC, Font P, Muñoz-Gomariz E, Collantes-Estevez E (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74(3):254–258
Acknowledgment
We would like to thank Ms. Nithya Joseph, Department of Biostatistics, Christian Medical College, for the assistance provided in the statistical analysis.
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sandhya, P., Danda, D., Mathew, J. et al. Outcome of patients with seronegative spondyloarthritis continuing sulphasalazine and methotrexate after a short course of infliximab therapy—experience from a tertiary care teaching hospital in South India. Clin Rheumatol 30, 997–1001 (2011). https://doi.org/10.1007/s10067-011-1723-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1723-4